{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:35:15Z","timestamp":1789724115436,"version":"4.0.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"Importance<\/jats:title>Prenatal antiseizure medication (ASM) exposure has been associated with adverse early neurodevelopment, but associations with a wider range of psychiatric end points have not been studied.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the association between prenatal exposure to ASM with a spectrum of psychiatric disorders in childhood and adolescence in children of mothers with epilepsy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, population-based register study assessed 4\u202f546\u202f605 singleton children born alive in Denmark, Finland, Iceland, Norway, and Sweden from January 1, 1996, to December 31, 2017. Of the 4\u202f546\u202f605 children, 54\u202f953 with chromosomal disorders or uncertain birth characteristics were excluded, and 38\u202f661 children of mothers with epilepsy were identified. Data analysis was performed from August 2021 to January 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Prenatal exposure to ASM was defined as maternal prescription fills from 30 days before the first day of the last menstrual period until birth.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome measure was diagnosis of psychiatric disorders (a combined end point and 13 individual disorders). Estimated adjusted hazard ratios (aHRs) using Cox proportional hazards regression and cumulative incidences with 95% CIs are reported.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 38\u202f661 children of mothers with epilepsy (16\u202f458 [42.6%] exposed to ASM; 19\u202f582 [51.3%] male; mean [SD] age at the end of study, 7.5 [4.6] years), prenatal valproate exposure was associated with an increased risk of the combined psychiatric end point (aHR, 1.80 [95% CI, 1.60-2.03]; cumulative risk at 18 years in ASM-exposed children, 42.1% [95% CI, 38.2%-45.8%]; cumulative risk at 18 years in unexposed children, 31.3% [95% CI, 28.9%-33.6%]), which was driven mainly by disorders within the neurodevelopmental spectrum. Prenatal exposure to lamotrigine, carbamazepine, and oxcarbazepine was not associated with an increased risk of psychiatric disorders, whereas associations were found for prenatal exposure to topiramate with attention-deficit\/hyperactivity disorder (aHR, 2.38; 95% CI, 1.40-4.06) and exposure to levetiracetam with anxiety (aHR, 2.17; 95% CI, 1.26-3.72) and attention-deficit\/hyperactivity disorder (aHR, 1.78; 95% CI, 1.03-3.07).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam. This study provides reassuring evidence that lamotrigine, carbamazepine, and oxcarbazepine are not associated with long-term behavioral or developmental disorders but cannot rule out risks with higher doses.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.0674","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T15:02:36Z","timestamp":1681743756000},"page":"568","source":"Crossref","is-referenced-by-count":75,"title":["Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders"],"prefix":"10.1001","volume":"80","author":[{"given":"Julie Werenberg","family":"Dreier","sequence":"first","affiliation":[{"name":"National Centre for Register-Based Research, School of Business and Social Science, Aarhus University, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte-Helene","family":"Bj\u00f8rk","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Alvestad","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"National Center for Epilepsy, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Gissler","sequence":"additional","affiliation":[{"name":"Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland"},{"name":"Region Stockholm, Academic Primary Health Care Centre, Stockholm, Sweden"},{"name":"Karolinska Institute, Department of Molecular Medicine and Surgery, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannicke","family":"Igland","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"},{"name":"Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit K.","family":"Leinonen","sequence":"additional","affiliation":[{"name":"Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelian","family":"Sun","sequence":"additional","affiliation":[{"name":"National Centre for Register-Based Research, School of Business and Social Science, Aarhus University, Aarhus, Denmark"},{"name":"Department of Neurology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia"},{"name":"Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Christensen","sequence":"additional","affiliation":[{"name":"National Centre for Register-Based Research, School of Business and Social Science, Aarhus University, Aarhus, Denmark"},{"name":"Department of Neurology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"noi230018r1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/pds.v29.8","article-title":"Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: a study in the five Nordic countries, United States, and Australia.","volume":"29","author":"Cohen","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"noi230018r2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s13311-016-0464-0","article-title":"Use of antiepileptic drugs during pregnancy: evolving concepts.","volume":"13","author":"Pennell","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"6","key":"noi230018r3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/pds.v27.6","article-title":"Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014.","volume":"27","author":"Kurko","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"noi230018r5","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations.","volume":"362","author":"Jentink","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"noi230018r6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"24","key":"noi230018r7","doi-asserted-by":"publisher","first-page":"e3232","DOI":"10.1212\/WNL.0000000000010993","article-title":"Antiseizure medication use during pregnancy and risk of ASD and ADHD in children.","volume":"95","author":"Wiggs","year":"2020","journal-title":"Neurology"},{"issue":"23","key":"noi230018r8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1212\/01.wnl.0000339399.64213.1a","article-title":"Autism spectrum disorders following in utero exposure to antiepileptic drugs.","volume":"71","author":"Bromley","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"noi230018r9","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","article-title":"Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France.","volume":"10","author":"Coste","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"noi230018r10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability.","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi230018r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6606","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit\/hyperactivity disorder in offspring.","volume":"2","author":"Christensen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"noi230018r12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.yebeh.2013.08.001","article-title":"Fetal antiepileptic drug exposure: adaptive and emotional\/behavioral functioning at age 6years.","volume":"29","author":"Cohen","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"16","key":"noi230018r13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"noi230018r14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi230018r15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamaneurol.2021.1583","article-title":"Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study.","volume":"78","author":"Meador","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi230018r16","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00415-020-09764-w","article-title":"Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure.","volume":"267","author":"Huber-Mollema","year":"2020","journal-title":"J Neurol"},{"issue":"6","key":"noi230018r17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jamaneurol.2017.5035","article-title":"Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children.","volume":"75","author":"Elkj\u00e6r","year":"2018","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi230018r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25570","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones.","volume":"3","author":"Daugaard","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"noi230018r19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs.","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"noi230018r20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamapsychiatry.2019.3523","article-title":"Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence.","volume":"77","author":"Dalsgaard","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"noi230018r21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks.","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J"},{"issue":"5","key":"noi230018r22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamapsychiatry.2014.16","article-title":"A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders.","volume":"71","author":"Pedersen","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"noi230018r23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/epi.2015.56.issue-7","article-title":"Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy.","volume":"56","author":"Wood","year":"2015","journal-title":"Epilepsia"},{"issue":"8","key":"noi230018r24","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/epi.12226","article-title":"Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.","volume":"54","author":"Veiby","year":"2013","journal-title":"Epilepsia"},{"key":"noi230018r25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ntt.2016.01.001","article-title":"Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine.","volume":"54","author":"Deshmukh","year":"2016","journal-title":"Neurotoxicol Teratol"},{"issue":"2","key":"noi230018r26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/cdev.2007.78.issue-2","article-title":"Parental sensitivity and attachment in children with autism spectrum disorder: comparison with children with mental retardation, with language delays, and with typical development.","volume":"78","author":"van Ijzendoorn","year":"2007","journal-title":"Child Dev"},{"issue":"4","key":"noi230018r27","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1212\/WNL.0000000000004857","article-title":"Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study.","volume":"90","author":"Hernandez-Diaz","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"noi230018r28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"noi230018r29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jclinepi.2013.02.011","article-title":"Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations.","volume":"66","author":"Skurtveit","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"18","key":"noi230018r30","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"noi230018r31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.reprotox.2012.05.038","article-title":"Preliminary findings of the developmental effects of in utero exposure to topiramate.","volume":"34","author":"Rihtman","year":"2012","journal-title":"Reprod Toxicol"},{"issue":"12","key":"noi230018r32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","article-title":"In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring.","volume":"89","author":"Bech","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi230018r33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2023.01.008","article-title":"Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study.","volume":"105","author":"Knight","year":"2023","journal-title":"Seizure"},{"issue":"8","key":"noi230018r34","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/epi.v62.8","article-title":"Neurodevelopmental outcomes in children exposed to newer antiseizure medications: a systematic review.","volume":"62","author":"Knight","year":"2021","journal-title":"Epilepsia"},{"issue":"7","key":"noi230018r35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/adc.2009.176990","article-title":"Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.","volume":"96","author":"Cummings","year":"2011","journal-title":"Arch Dis Child"},{"issue":"5","key":"noi230018r36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00001648-200109000-00006","article-title":"Do pregnant women report use of dispensed medications?","volume":"12","author":"Olesen","year":"2001","journal-title":"Epidemiology"},{"issue":"3","key":"noi230018r37","first-page":"798","article-title":"Data resource profile: The Danish National Prescription Registry.","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"noi230018r4","unstructured":"Medicines and Healthcare Products Regulatory Agency. Antiepileptic Drugs: Review of Safety of Use During Pregnancy. Medicines and Healthcare Products Regulatory Agency; 2021. Accessed March 4, 2023. https:\/\/www.gov.uk\/government\/publications\/public-assesment-report-of-antiepileptic-drugs-review-of-safety-of-use-during-pregnancy\/antiepileptic-drugs-review-of-safety-of-use-during-pregnancy"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2803245\/jamaneurology_dreier_2023_oi_230018_1686342398.85706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:05:43Z","timestamp":1686582343000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2803245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.0674","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}